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Summary Forty-four childred aged 3-13 years with Murphy stage III B cell non-Hodgkin's lymphoma were
treated between May 1986 and December 1989. All have been followed up for at least 12 months. The primary
site was the abdomen in 37 children, 24 of whom had involvement of other organs or nodal disease outside the
abdomen. Twenty-eight received a standard dose regimen (regimen 1) and 16 had a more intensive regimen
(regimen 2 - MACHO). Fourteen patients (87%) who received MACHO had extensive multi-organ disease
compared to 15 (53%) on regimen 1. Most of the latter had ony pleural effusions.
Thirty-four children are alive relapse free and considering the early relapse pattern in this disease are
probably cured (actuarial event free survival = 76%).
There has been one relapse (6%) after MACHO, but three toxic deaths. Six patients (21%) on the less
intensive regimen have relapsed.
Morbidity was high in terms of infection and need for haematological support and hospitalisation in the one
third of children electively given the more intensive regimen.
It is concluded that the vast majority of children with stage III disease who have disease limited to lymph
nodes are curable with a moderately intensive regimen. Those with multiorgan involvement probably require
more intensive treatment. It is therefore of importance to clarify prognostic factors in these patients to
determine who can be cured with a less intensive regimen and who requires further dose intensification.
Over the past decade the cure rate in children with non-
localised B cell non-Hodgkin's lymphoma (NHL) has im-
proved due to a moderate intensification of drug dose and
the introduction of high dose methotrexate with folinic acid
rescue (Murphy et al., 1989). Some groups of patients remain
a therapeutic problem such as those with CNS disease at
presentation or a leukaemia-like syndrome (Sariban et al.,
1983; Murphy, 1980). There is debate, however, about the
curability of patients with Murphy stage III disease who by
definition have neither bone marrow nor central nervous
system involvement.
Using the Murphy classification patients with stage III
disease may have widely differeing tumour extent (Murphy,
1980). This can range from a localised abdominal tumour
which is deemed unresectable on the grounds of a desire to
avoid unnecessary intestinal resection rather than surgical
feasibility, to a patient with extensive abdominal disease,
with renal and splenic involvement and pleural effusions. It
seems likely that, as in most solid tumours and haemato-
logical malignancies, initial disease bulk is of prognostic
significance. Consequently, treatment for some patients with
small volume disease may be excessively intensive, carrying
the unneccessary risk of sterilisation and second tumours.
Conversely, standard treatment will be inadequate for a sub-
group with more extensive disease for whom further dose
intensification, possibily including megatherapy and auto-
logous bone marrow rescue may be indicated.
The results in patients with stage III B cell NHL who were
treated by United Kingdom Children's Cancer Study Group
(UKCCSG) centres over a 4 year period are reviewed and
provide the background for the current prospective study
(UKCCSG NHL 90) which evaluates prognostic factors
within this group of patients.
Patients and methods
Forty-four children with stage III B cell NHL aged 3 months
to 16 years - (median 8 years), who presented sequentially at
participating UKCCSG centres were treated according to the
UKCCSG NHL 86-01 or 86-02 regimens. The primary site of
disease was the abdomen in 39 children. Other involved sites
are shown in Table I. Seven patients with B cell disease
presented with atypical primary sites - liver (one), bladder
(one), mediastinum (four).
B cell NHL was defined as either 'high grade, diffuse, small
non cleaved lymphoblastic' or 'large cell immunoblastic lym-
phoma' (working formulation). These are equivalent, respec-
tively, to 'small non cleaved Burkitt/non Burkitt' and 'large
cell' as classified by the American Children's Cancer Group
(CCG) and Paediatric Oncology Group (POG). In most cases
B cell immunophenotype was demonstrated on either fixed
tissue or cell suspension and monoclonality of surface immu-
noglobulin expression was demonstrated. Three patients with
mediastinal primary disease had 'large cell' lymphoma, two
of which were of K1( + ), B phenotype.
Diagnostic tissue was obtained at laparotomy in 21
patients, by biopsy of other involved tissue in 19 and by
examination of pleural fluid aspirate in five. Routine staging
investigations included bone marrow aspirate at one or more
sites and cerebrospinal fluid examination. Extent of nodal
disease was evaluated clinically and by ultrasound or CT
scan.
It has been suggested (Philip et al., 1987) that the outcome
in patients with Murphy stage III disease may be predicted
by the extent of the initial tumour. The 'Lyon classification'
separates patients into IIIA and IIIB sub-groups. These are
defined in Table II. Using this classification, which applies
only to patients with primary intra-abdominal nodal disease
there were 25 stage IIIB and 12 stage IIIA.
Details of the two treatment regimens are shown in
Figures 1 and 2. Regimen 1 is a modification of the standard
CHOP regimen adding moderate dose methotrexate with
folinic acid rescue and courses of cytarabine, thioguanine,
etoposide and asparaginase. The majority of chemotherapy
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Table I Primary and distant sites oflymphoma inpatients given the less intensive regimen 1 and the more intensive
regimen 2
Distant sites
Pleural Distant
Primary site effusion Kidney Liver Spleen Bone nodes Others
Reginen 1
Abdomen (25) 5 4 4 3 1 6 - Pancreas
- Mediastinum and orbit
- Liver surface
Bladder (1) - -
Liver (1) - 1
Mediastinum (1)
- Pericardium
Regimen 2
Abdomen (12) 5 0 3 2 _ 4 - Ovary and chest wall
- Mediastinum and jaw
- Lung and thigh
- Mediastinum, orbit and
abdominal wall
Mediastinum (4) 1 0 2 2 - 2 - Pericardium
was given as an out-patient. By contrast, in MACHO there is
considerable dose escalation with administration ofhigh dose
methotrexate between courses of myelosuppressive therapy.
In-patients admission was required both for administration
of treatment and for the almost inevitable treatment of feb-
rile neutropaenic episodes.
From the outset of the study two protocols were recom-
mended. Regimen 1 was designed for the majority of
patients. Regimen 2 was a new high dose intensity protocol
to be used by a limited number of centres for patients
considered to be 'high risk'. This decision was due to a
reluctance to continue using a less intensive regimen for
patients with very bulky disease or multi-organ involvement.
Table II The Lyon classification of stage III abdominal B cell
NHL
IIIA
Abdominal primary, nodal disease confined to mesenteric node
involvement±ascites
IIIB
Abdominal primary with extensive nodal involvement and
extra-nodal disease e.g. pleural effusion, distant or retro-
peritoneal nodes, kidney, liver, spleen, ovary, bone
Unfortunately this clinical subdivision was subjective and
moreover some centres were reluctant to use Regimen 2 in
any children due to the anticipated morbidity.
Results
Complete remission (CR) was confirmed with X-ray, CT scan
or ultrasound. Other imaging procedures such as bone scan
were used where appropriate. In only two patients was initial
surgical excision ofthe abdominal primary tumour attempted
and radiotherapy was not used in any patients. Forty-one/44
patients achieved complete remission. In addition one of
three patients who was an early toxic death was found to be
in complete remission at autopsy.
Due to the high chemosensitivity of this tumour and the
often bulky disease, tumour lysis syndrome was anticipated.
Abnormalities in renal function were apparent in seven
patients despite hyperhydration and allopurinol. In one of
these cases renal dysfunction was exacerbated by nodal obs-
truction of the ureters. Two patients, including the latter,
required elective dialysis during induction and one patient
was managed with haemofiltration. There were no deaths
primarily due to tumour lysis syndrome although acute renal
CHEMOTHERAPY SCHEDULE. UKCCSG NHL '86 REGIMEN 1
WEEKS 0 1 2 3 4 5 6 7 8 10 and 19 13 and 22 16 and 25
CYCLOPHOSPHAMIDE
(1 G/m2)
DOXORUBICIN
(50 mg/M2)
VINCRISTINE
1.5 mg/mr2)
PREDNISOLONE
(100 mg/M2 x 7)
ETOPOSIDE
(150 mg/Mr2)
METHOTREXATE
(500 mg/M2)
FOLINIC ACID
CYTARABINE
THIOGUANINE
ASPARAGINASE
(5000 i.u./m2/d x 7)
IT MTX
LIZ.Nl EZ. EZ..
iiiiiii 100 mg/m2 iv bd
isisiii x 14doses
1 175 mg/m2/d x 7
Hiii 150 mg/m2 x 5
1ZZ75mg/m2/d x 5
Figure 1 Outline of chemotherapy regimen 1.
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CHEMOTHERAPY SCHEDULE, UKCCSG NHL '86
REGIMEN 2 (MACHO)
DAYS 1 2 3 4
CYCLOPHOSPHAMIDE iv
(300 mg/M2 bd) bolus
MESNA
(600 mg/m2/day)
infusion x 4)
VINCRISTINE iv
(1.5 mg/m2)
DOXORUBICIN iv
(50 mg/M2)
METHOTREXATE (MTX)
(2.5 g/m2 iv)
1/5 over 3 hrs
4/5 over 21 hrs
7 11 15 21
+
FOLINIC ACID
(15 mg iv 6 hrly)
x 10 doses)
CYTARABINE
(2 g/m2 12 hrly)
infus. over 3 hrs
x 6 doses
IT CYTARABINE
IT HYDROCORTISONE
IT MTX
Cycle repeated x 3
Figure 2 Outline of chemotherapy regimen 2 (MACHO).
failure contributed to one toxic death. This patient developed
severe sepsis and gastrointestinal toxicity shorty after initial
therapy. An unexplained toxic epidermal necrolysis also
developed and the patient died of multi-organ failure at 3
weeks. The second death was due to septicaemia and dissem-
inated fungal infection at 4 weeks. The third was a late death
at 6 months due to measles, pneumonitis and liver failure.
This patient had failed to achieve CR at the primary media-
stinal site. Complications of the two regimens are listed in
Table III.
There have been seven relapses. One out of 16 patients
who received the more intensive regimen, MACHO, relapsed
in the bone marrow and liver 8 months after diagnosis. Six
out of 28 treated with regimen 1 have relapsed. There were
two recurrences at the primary abdominal site. In one case
also in the testis. Two were in the central nervous system, of
whom one also had ocular involvement and one disease in
the orbit at relapse. The fifth relapsed in the orbit and the
sixth in the mediastinum and lungs. As is characteristics of
this disease, all relapses occurred early, namely 6, 5, 8, 5, 19
and 7 months after diagnosis.
The actuarial event free survival for the two regimens is
shown in Figure 3. For regimen 1, EFS = 78% (95% CI
57-90%) and regimen II, EFS = 75% (95% CI 46-90%).
When patients with abdominal disease are analysed on the
basis of Lyon stage, 11 of the 12 stage IIIA remain disease
free, EFS = 92% (95% CI 54-99%), as do 17/25 stage IIIB,
EFS = 71% (95% CI 49-85%). There is no significant differ-
ence between any of these sub-groups (Figure 4). It is of note
however that three patients on regimen 1 were classified IIIB
Table III Complication associated with the two chemotherapy regimens
Febrile Nutritional Toxic
neutropeniaa supportb Other death
Regimen I
n = 28 45% 25% encephalopathy 0
(2 at
diagnosis)
Regimen 2
n = 16 92% 46% seizures, hyperten- 3
25% received amphoterin sion intestinal stric-
ture aspergillosis
aPercentage = number who required antibiotics at any time/total number ofpatients.
bTotal parenteral nutrition or nasogastric feeding. Percentage = number who required
support/total number ofpatients.
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Figure 3 Event free survival for all 43 patients with Murphy
Stage III disease, given either Regimen 1 or 2. Survival is plotted
against time after diagnosis.
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Figure 4 Outcome by site and extent of intra-abdominal disease
based on the Lyon classification.
on the basis of pleural effusion alone. In addition, one had
equivocal liver involvement on CT scan (not biopsied) and a
fifth had deposits on the surface, rather than within the liver.
None of these five had evidence of bulky extra-abdominal or
other organ involvement. By contrast, all the patients with
stage IIIB disease who received the MACHO protocol had
extensive multi-organ involvment.
Discussion
Cure rates in localised NHL using chemotherapy alone are
very high irrespective of the minor variations in the nature of
the chemotherapy given (Jenkin et al., 1984; Meadows et al.,
1989). In this group of patients the emphasis is therefore on
designing treatment programmes with minimal early and late
morbidity. This may involve the omission of alkylating
agents with the substitution of etoposide or methotrexate or
the omission of anthracyclines. Whether the emphasis should
be on avoiding infertility and second tumours or late cardio-
toxicity (Praga et al., 1979; Vathaire F de et al., 1989;
Kreuser et al., 1988) is debatable and different groups are
following both avenues of investigation.
In the case of stage III disease, or stage IV with a low
degree of marrow involvement and no CNS disease, the issue
is more complex. From the French LMB studies it is clear
that increasing the doses of cyclophosphamide, cytarabine
and methotrexate has had a dramatic impact on cure rates.
However, the question as to whether there are sub-groups
which require further intensification of therapy or, con-
versely, less intensive treatment cannot be answered by either
the current study or previously published data. Inevitably,
the numbers of patients are limited and most published series
are small. Most protocols are based on a cyclophosphamide,
anthracycline and methotrexate combination with a variety
of additional agents. The overall disease-free survival at 2
years i.e. probable cure, range from 62% to 81%. The former
figure was achieved with the LSA2L2 regimen which has been
demonstrated in a previous randomised study to be inferior
to the conventional CHOP-based regimen (Anderson et al.,
1982). The best results have been reported by the French
'LMB' group (Patte et al., 1986; Patte et al., 1990) and the St
Judes group (Murphy et al., 1986). Sub-group analysis in the
LMB studies dividing patients on the basis of the extent of
disease have confirmed the inferior outcome where organs
beyond the intestine are involved, such as liver, spleen,
reproductive organs or mediastinum, i.e., Lyon group B
(Rodary et al., 1988). It should be noted that some recent
series have contained a disproportionate number of patients
with more limited disease, explaining the good outcome (Fin-
lay et al., 1989).
Because investigators in the UKCCSG study were free to
allocate children to either of two protocols it is impossible to
draw conclusions as to the superior efficacy of the more
intensive MACHO regimen. The outcome of patients with
the less intensive regimen 1 was excellent although it is
apparent that a smaller proportion of these patients had truly
extensive multi-organ involvement. By contrast, the main
reason for allocating children to regimen 2 was more exten-
sive disease at presentation and hence there were a higher
number of poor risk patients given the MACHO protocol.
Protocol 1 was based on traditional CHOP regimen with
the addition of intermediate dose methotrexate and a com-
bination of drugs shown to have efficacy in lymphoblastic
leukaemia, namely low dose cytarabine, thioguanine and
teniposide. The necessity for this many drugs is unclear and
good results can be achieved using regimens based on only
three drugs, namely cyclophosphamide, high dose methotrex-
ate and vincristine, provided doses are high enough. In the
MACHO regimen the number of drugs was reduced com-
pared to regimen 1 but the dose increased following the
strategy of Murphy et al. (1986) and the LMB group. Work
with very high dose chemotherapy using autologous bone
marrow rescue has confirmed the efficacy of dose escalation
in advanced B cell lymphoma (Philip et al., 1985). In the
MACHO regimen the strategy of high dose intensity, with
rapid drug delivery, is applied. There is increasing evidence
that delivering bigger doses of chemotherapy in shorter
periods of time will improve outcome (Dembo, 1987). The
administration of methotrexate 12-15 days after highly
myelosuppressive chemotherapy was an unconventional
approach which enabled the interval between exposure of
tumour to active chemotherapeutic agents to be minimised.
With a tumour such as B cell NHL, where there is a high
growth fraction tumour regrowth may recur during a 21-28
day gap between pulsed chemotherapy. With folinic acid
rescue high dose methotrexate is non-myelosuppressive and
can therefore be given despite low blood counts.
Inevitably the toxicity of the MACHO regimen was high
with the risk of severe sepsis, mucositis, gastrointestinal pro-
blems and prolonged periods in hospital. This was due to the
pulses of cyclophosphamide/doxorubicin and high dose cyta-
rabine, not the high dose methotrexate. These complications
are common to most modem intensive chemotherapy regi-
mens and are the reason why it is essential to determine
which patients with stage III disease may be spared such
treatment.
The National Cancer Institute (NCI) has recently sug-
gested subdividing stage III patients along the lines of the
Lyon classification. NCI stage IIIA is 'unresected intra-
abdominal tumour and epidural tumour, not otherwise stage
IV, i.e. no CSF blasts nor cranial nerve palsy'. IIIB is 'intra-
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and extra-abdominal tumour except bone marrow' (Magrath,
1989). This system has not yet been clinically assessed. It is
of note that although the presence of a pleural effusion has
been said to be an adverse prognostic factor (Sandlund et al.,
1990) this may not be the case in the absence of other
extranodal disease.
Because in the present study patients were not randomly
allocated to the more or less intensive regimens, firm con-
clusions cannot be drawn regarding who needs more therapy.
It is likely that the tendency for investigators to allocate
those with more bulky disease to regimen 2 probably improv-
ed the outcome in this group. Clarification of prognostic
factors is urgently required.
In the current co-operative UKCCSG/SFOP (French
Society of Paediatric Oncology) study all patients with stage
IIIB cell NHL receive the LMB 84 regimen and prognostic
factors are being evaluated prospectively. The latter include
initial tumour bulk, serum LDH levels, response to first
exposure to chemotherapy, time to achieve complete response
and nutritional status at presentation. It is hoped that an
answer will be reached in 3-5 years and the sub-group with
a favourable outcome can then be considered for elective
treatment with a less intensive regimen. Conversely, those
with a poor prognosis will be treated with early megatherapy.
The UKCCSG is supported by the Cancer Research Campaign.
We are grateful to Tereza Gladwell for help preparing the manu-
script.
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